SCHEMBL8230171

SCHEMBL8230171

CN1CCCC(n2cnc(C(=O)N3CCN(C(=O)OC(C)(C)C)C[C@H]3Cc3ccccc3)c2-c2ccccc2)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABHD6 Q9BV23 1/20 0.45
DAGLA Q9Y4D2 1/20 0.45
PARP1 P09874 1/20 0.41
DPP4 P27487 1/20 0.39
EGFR P00533 1/20 0.39
SRC P12931 1/20 0.39
NR1H2 P55055 2/20 0.38
NR1H3 Q13133 2/20 0.38
HPGDS O60760 2/20 0.38
ACKR3 P25106 1/20 0.38
USP30 Q70CQ3 2/20 0.37
BCHE P06276 2/20 0.37
HTR6 P50406 2/20 0.37
HDAC1 Q13547 1/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA4 P22748 2/20 0.37
CA9 Q16790 2/20 0.37
PRMT5 O14744 1/20 0.37
HCAR1 Q9BXC0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13705167 0.92 ABHD6 (0.47) ABHD6DAGLAPARP1DPP4EGFR
SCHEMBL8238426 0.92 ABHD6 (0.47) ABHD6DAGLAPARP1DPP4EGFR
SCHEMBL13341101 0.91 ABHD6 (0.45) ABHD6DAGLAPARP1DPP4EGFR
SCHEMBL13341129 0.91 ABHD6 (0.43) ABHD6DAGLAPARP1DPP4EGFR
SCHEMBL8239198 0.91 NR1H2 (0.44) ABHD6DAGLAPARP1DPP4EGFR
SCHEMBL8235955 0.91 ABHD6 (0.44) ABHD6DAGLAPARP1DPP4EGFR
SCHEMBL8240230 0.91 ABHD6 (0.43) ABHD6DAGLAPARP1DPP4EGFR
SCHEMBL8239273 0.90 PARP1 (0.49) ABHD6DAGLAPARP1DPP4EGFR
SCHEMBL8238139 0.90 ABHD6 (0.42) ABHD6DAGLAPARP1NR1H2NR1H3
SCHEMBL3493838 0.90 CA1 (0.41) CA1CA2CA4CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-13 US disclosed
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-13 US disclosed
WO-2007094513-A2 CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension REN, AGTR1, AGTR2 ABHD6 2780/4885DAGLA 4388/4885PARP1 2353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.